EXOT official

$0.01 per transaction. 3-second blocks. Millions of users, thousands of projects, all on BSC. EXOT's modules ship and upgrade independently. MPC wallets, zk-SNARK KYC, multi-sig security guard every asset without slowing anything down. Fast doesn't mean fragile here. See the architecture.

A startup pitches. The Scientific Advisory Board and AI agents stress-test the science. Token holders vote on-chain. EXOT then tracks every milestone that follows. Four steps, and no single gatekeeper controls the outcome. Due diligence, decentralized. See the full process.

A decade, a billion dollars, and 90% failure, not from bad science, but from a funding gap only VCs and pharma giants could survive. EXOT opens that market with DAO-governed DeSci transparency and RWA-backed stability, giving individual investors real access for the first time. The exclusive market, opened. 🧬 Read the full thesis.

35% targets cancer, delivering drugs precisely enough to spare the side effects chemo can't avoid. 28% goes to regenerative medicine. 22% crosses the blood-brain barrier for conditions like Alzheimer's and Parkinson's. 15% builds early-detection liquid biopsy tools. Exosome technology, allocated with purpose. 🧬 Explore EXOT's focus areas.

90% of promising drug candidates die in the Valley of Death, not from bad science, but from a funding gap that swallows a billion dollars and a decade. This is exactly the structural problem EXOT was built to solve, with DeSci transparency and RWA stability fused into one protocol. Watch this space. 🧬 Look into EXOT.

Corporate value that rises should show up directly in the token, not stay locked behind traditional structures. EXOT is the world's first hybrid framework combining DeSci and RWA, investing treasury capital directly into tangible equity of biotech companies fighting incurable disease. Real growth, reflected on-chain. Explore the framework. 👀🔍🔍

Over 90% of promising drug candidates fail, not from bad science, but from a funding gap at the earliest stage. EXOT built its protocol specifically for the Valley of Death, combining DeSci transparency with RWA stability into one hybrid investment platform. The barrier was never the science. 🧬 Read the paradigm shift.

Bio companies get funding that survives the Valley of Death, plus real network support beyond capital. Investors get access to early-stage biotech that was historically locked away, with liquidity through tokenized equity instead of years of waiting. Two sides, one shared upside. 🧬 See where you fit in EXOT.

Institutional or retail, the staking pool doesn't discriminate on access, only on scale. Both stake EXOT into a bio company's staking pool. Both earn interest back. The difference is investment size, not opportunity. Interest rates aren't fixed either. Each bio company receiving investment can carry its own rate, shaped by how its project actually performs. Two tiers, one mechanism, one shared upside. 🧬 Explore staking on EXOT.

An investment firm locks in capital. EXOT tokens flow to a DAO Treasury with real governance weight, not just voting tokens. Bio companies get funded. When profits come, 100% of rights and 80% of returns flow back to the investors who backed it. Structured, not improvised. 🧬 See the treasury model.